811 ORAL ASCENT: A double-blinded randomized study of DN-101 (highdose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC)

Double-Blinded Randomized Study of High-

Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators

✍ Kibel, A.S. 📂 Article 📅 2008 🏛 Elsevier Science ⚖ 55 KB

Double-Blinded Randomized Study of High-

Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators

✍ Andriole, G.L. 📂 Article 📅 2007 🏛 Elsevier Science ⚖ 63 KB

Intermittent chemotherapy in patients wi

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer : Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

✍ Tomasz M. Beer; Christopher W. Ryan; Peter M. Venner; Daniel P. Petrylak; Gurkam 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## BACKGROUND. Survival in patients with metastatic, chemotherapy‐naive, androgen‐independent prostate cancer (AIPC) is improved with 10 to 12 cycles of docetaxel‐containing chemotherapy but further management is undefined. In the current study, the authors examined retreatment with th

Intermittent chemotherapy in patients wi

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel: Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD, ASCENT (AIPC Study of Calcitriol Enhancing Taxotere) Investigators, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR

✍ Donald L. Trump 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 42 KB

2103 ORAL A randomized, double-blind pha

2103 ORAL A randomized, double-blind phase 2 study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)

✍ S. Chan; A. Stopeck; A.A. Joy; S. Verma; A. Lluch; F.K. Liau; S. Kim; P.W. Bycot 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Double-blinded randomized study of high-

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators: Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, ASCENT Investigators, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR

✍ Donald L. Trump 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 42 KB